Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology

Search Medical Condition
Please enter condition
Please choose location

Thrombocytopenic Clinical Trials

A listing of Thrombocytopenic medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (59) clinical trials

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients. All of the subjects in this study receive Hetrombopag.


A Study of Eltrombopag in Patients With CMML and Thrombocytopenia

All eligible patients will be treated with eltrombopag for a minimum of twelve weeks and a maximum of 24 months.


A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

The purpose of this study is to obtain information on efficacy, safety and Pharmacokinetics (PK)/Pharmacodynamics (PD) of Hetrombopag over 14 days in Chinese patients with chronic ITP.


Study to Evaluate Safety Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia

The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.


PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

Study Treatments: Epsilon aminocaproic acid (EACA) vs. standard prophylactic platelet transfusions. Study Title: Randomized Trial of Epsilon Aminocaproic Acid versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients with Hematological Malignancies. (PROBLEMA trial: PRevention Of BLeeding in hEmatological Malignancies with Antifibrinolytic agents (epsilon aminocaproic acid). Phase: Randomized Phase ...


A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

This is an open-label Phase III extension study to evaluate the long-term safety of eltrombopag in pediatric patients with chronic ITP who previously participated in study TRA115450. This study will allow dosing of eltrombopag at an individualized dose for each subject based upon platelet count. The starting dose will be ...


Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers

Eligible subjects will provide written informed consent after which demographic and baseline clinical data will be recorded. Collection of whole blood and urine samples will be performed at one or more clinic visits from pregnant women carrying a single fetus with no known fetal abnormalities. Interim study visits will continue ...

Phase N/A

Association of Fc RIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

Immune thrombocytopenic purpura (ITP) is a autoimmune disorder in which a decreased number of circulating platelets (thrombocytopenia) manifests as a bleeding tendency, easy bruising (purpura), or extravasation of blood from capillaries into skin and mucous membranes (petechiae). In persons with ITP, platelets are coated with autoantibodies to platelet membrane antigens, ...


Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)

The objective of this study is to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long term impact of TTP.


Patients are needed to participate in a clinical research study for the treatment of Thrombocytopenia, Pancytopenia, Neutropenia, Hematologic Malignancy, Anemia

This protocol is designed for screening of subjects before a decision can be made as to their eligibility for one of the active Hematology Branch research protocols. Its purpose is to allow detailed investigation into the hematologic or oncologic problems of these subjects, and the status of other organ systems ...

Phase N/A